Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race

Executive Summary

Pfizer has seven immuno-oncology drugs in the clinic and an ambition to be the first drug maker to bring a PD-1/OX40/4-1BB triplet regimen into the clinic late this year or early next.


Related Content

Pfizer Takes Step Back With Avelumab, Step Forward On CAR-T
Pfizer’s Avelumab Poised For Speedy Review By FDA
Pfizer Is Back In The CTLA-4 Game Via Pact With OncoImmune
With Medivation, Pfizer Sees A Chance For More Combinations
Melanoma Approvals Break New Ground In Immunotherapy
Pfizer Oncology Strategy: An Investment Starts To Pay Off


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts